The Clinical Study Of S-1or5-fluorouracil Combined With Docetaxel In The Treatment Of Advanced Gastric Cancer

Objective：To compare the efficacy and adverse reaction of and docetaxel combinedwith5-fluorouracil in the treatment of advanced gastric cancer.Methods:Collection of102advanced gastric cancer patients confirmed by pathology,50patients in goup A treatedwith docetaxel combined with S-1regimen: S-180mg/m~2,orally twicedaily,d1-d14,Docetaxel75mg/m~2,d1,ivgtt,repeated every21d;52patients in goup Btreated with Docetaxel combined with5-fluorouracil regimen: CF400mg/m~2, d1, ivgtt,5-Fu400mg/m~2,d1,ivgtt,5-Fu2400-3000mg/m~2,CIV(46h), Docetaxel50mg/m~2,d1,ivgtt,repeated every14d.The recent efficacy, behavioral states, adverse reaction,ProgressionFree Survival(PFS),over all survival(OS) of the two regimens were compared andanalyzed.Results:The response rate(RR)of group A and group B were16%and19.23%,Difference between two groups has no statistical significance (P=0.623). Thedisease control rate(DCR) of two groups were76%and78.85%,Difference has nostatistical significance (P=0.731).The median PFS of group A and group B were6.2months and5.5months, Difference has no statistical significance (P=0.801).The mediansurvival time of group A and group B were10.5months and9.5months,Difference has nostatistical significance (P=0.286).The improvement rate of behavioral states of group Aand group B were36%and17.31%, Difference has statistical significance (P=0.032). Themain adverse events were bone marrow suppression and gastrointestinal reactions. Theincidence of adverse reaction was similar between the two groups.Conclusion:The recentefficacy of two regimens were similar in treating patients with advanced gastric cancer.Regimen A was better than regimen B in the physical state.The adverse reaction of twogroups were similar.